Improving Total Shoulder Arthroplasty
common.study.values.description
“Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)”
This is a phase IV , randomized, single-blind, single-center study comparing patient related outcomes such as postoperative pain and opioid usage for patients who receive ISB 's containing liposomal bupivacaine (ExparelAR) plus 0.5% bupivacaine HCL versus 0.5% bupivacaine HCL undergoing total shoulder arthroplasty. The objective of this study is to compare opioid utilization and pain management of patients who receive Exparel in an ISB vs standard 0.5% bupivacaine HCL during the initial 72 --a?? hour post --a?? operative period. Additionally, to understand the duration of block after addition of ExparelAR to bupivacaine in an Interscalene block after TSA.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Liposomal Bupivacaine
Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
Drug - 0.5% Bupivacaine HCL
0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
participant.views.study.view.additional
participant.views.study.view.scientific-title
Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)
common.study.values.clinical-trial-id
NCT03913091
participant.views.study.view.id
dPN96a
